Zhejiang East Asia Pharmaceutical , Ltd. EBIT

The latest EBIT for 605177.SS is $-150M as of June 2026. That compares with $-180M in the prior-year period — up 17.5% year over year. That is below the Healthcare sector average of $130B. Investors often review this figure alongside Zhejiang East Asia Pharmaceutical , Ltd.'s historical trend and sector peers before judging valuation or financial health.

Over the past year, 605177.SS's EBIT moved from $-180M to $-150M — a 17.5% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Zhejiang East Asia Pharmaceutical , Ltd.'s operating scale or balance-sheet position.

Against Healthcare companies, 605177.SS currently prints $-150M for EBIT, while the sector average sits near $130B. That is roughly 100.1% below the sector mean. Large gaps often invite a closer look at Zhejiang East Asia Pharmaceutical , Ltd.'s growth, margins, and balance sheet.

A EBIT figure of $-150M for 605177.SS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $130B. Explore the charts below for those layers of context.

After noting 605177.SS's EBIT ($-150M), review year-over-year change from $-180M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.